Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series
Mark McAllister,
Talia Flanagan,
Susan Cole,
Andreas Abend,
Evangelos Kotzagiorgis,
Jobst Limberg,
Heather Mead,
Victor Mangas-Sanjuan,
Paul A. Dickinson,
Andrea Moir,
Xavier Pepin,
Diansong Zhou,
Christophe Tistaert,
Aristides Dokoumetzidis,
Om Anand,
Maxime Le Merdy,
David B. Turner,
Brendan T. Griffin,
Adam Darwich,
Jennifer Dressman,
Claire Mackie
Affiliations
Mark McAllister
Pfizer WWRD, Sandwich, Kent CT13 9NJ, UK
Talia Flanagan
UCB Pharma SA, 1420 Braine l’Alleud, Belgium
Susan Cole
Medicines & Healthcare Products Regulatory Agency, London E14 4PU, UK
Andreas Abend
Development Sciences and Clinical Supply, Merck & Co., Inc., Rahway, NJ 07033, USA
Evangelos Kotzagiorgis
European Medicines Agency, 1083 Amsterdam, The Netherlands
Jobst Limberg
Federal Institute for Drugs and Medical Devices (BfArM), 53175 Bonn, Germany
Heather Mead
AstraZeneca UK Limited, Macclesfield SK10 2NA, UK
Victor Mangas-Sanjuan
Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, E46100 Burjassot, Spain
Paul A. Dickinson
SEDA Pharmaceutical Development Sciences, Stockport SKB 3GX, UK
Andrea Moir
AstraZeneca UK Limited, Macclesfield SK10 2NA, UK
Xavier Pepin
AstraZeneca UK Limited, Macclesfield SK10 2NA, UK
Diansong Zhou
AstraZeneca Boston, Boston, MA 02451, USA
Christophe Tistaert
Janssen Research and Development, 2340 Beerse, Belgium
Aristides Dokoumetzidis
Department of Pharmacy, National and Kapodistrian University of Athens, 15784 Athens, Greece
Om Anand
Division of Biopharmaceutics, Office of New Drug Products, Office of Pharmaceutical Quality (OPQ), Centre for Drug Evaluation and Research, Food and Drug Administration (FDA), Silver Spring, MD 20903, USA
Maxime Le Merdy
Simulations Plus, Inc., Lancaster, CA 93534, USA
David B. Turner
Certara UK, Simcyp Division, Sheffield S1 2BJ, UK
Brendan T. Griffin
School of Pharmacy, University College Cork, T12 YT20 Cork, Ireland
Adam Darwich
Division of Health Informatics and Logistics, KTH Royal Institute of Technology, SE-164 40 Stockholm, Sweden
Jennifer Dressman
Fraunhofer Institute of Translational Medicine and Pharmacology, 60528 Frankfurt am Main, Germany
Claire Mackie
Janssen Research and Development, 2340 Beerse, Belgium
A webinar series that was organised by the Academy of Pharmaceutical Sciences Biopharmaceutics focus group in 2021 focused on the challenges of developing clinically relevant dissolution specifications (CRDSs) for oral drug products. Industrial scientists, together with regulatory and academic scientists, came together through a series of six webinars, to discuss progress in the field, emerging trends, and areas for continued collaboration and harmonisation. Each webinar also hosted a Q&A session where participants could discuss the shared topic and information. Although it was clear from the presentations and Q&A sessions that we continue to make progress in the field of CRDSs and the utility/success of PBBM, there is also a need to continue the momentum and dialogue between the industry and regulators. Five key areas were identified which require further discussion and harmonisation.